Literature DB >> 6838192

Comparison of concentrations of rifampin and a new rifamycin derivative, DL 473, in canine bone.

P Iversen, O S Nielsen, K M Jensen, P O Madsen.   

Abstract

Constant-infusion experiments were performed in 14 dogs to determine the penetration into bone of rifampin and a new C-3 substituted rifamycin, DL 473. The drugs were assayed in cortical bone and medulla from tibia-femur and cortical and cancellous bone from rib. After identical dosage, the concentrations of DL 473 appeared to be higher, except in the medulla, although the serum concentrations of rifampin were almost twice as high as those for DL 473. The concentrations of both drugs in all bone areas were several times higher than their minimum inhibitory concentrations against pathogenic Staphylococcus aureus.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6838192      PMCID: PMC186051          DOI: 10.1128/AAC.23.2.338

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  4 in total

1.  Experimental osteomyelitis. I. A description of the model.

Authors:  C W Norden
Journal:  J Infect Dis       Date:  1970-11       Impact factor: 5.226

Review 2.  Osteomyelitis: the past decade.

Authors:  F A Waldvogel; P S Papageorgiou
Journal:  N Engl J Med       Date:  1980-08-14       Impact factor: 91.245

3.  Antimycobacterial activity of rifampin under in vitro and simulated in vivo conditions.

Authors:  K D Stottmeier; G P Kubica; C L Woodley
Journal:  Appl Microbiol       Date:  1969-06

4.  Antibiotic concentrations in pus and bone of children with osteomyelitis.

Authors:  T R Tetzlaff; J B Howard; G H McCraken; E Calderon; J Larrondo
Journal:  J Pediatr       Date:  1978-01       Impact factor: 4.406

  4 in total
  3 in total

Review 1.  Systemic antibiotic therapy for chronic osteomyelitis in adults.

Authors:  Brad Spellberg; Benjamin A Lipsky
Journal:  Clin Infect Dis       Date:  2011-12-12       Impact factor: 9.079

2.  Dynamic PET-facilitated modeling and high-dose rifampin regimens for Staphylococcus aureus orthopedic implant-associated infections.

Authors:  Oren Gordon; Donald E Lee; Bessie Liu; Brooke Langevin; Alvaro A Ordonez; Dustin A Dikeman; Babar Shafiq; John M Thompson; Paul D Sponseller; Kelly Flavahan; Martin A Lodge; Steven P Rowe; Robert F Dannals; Camilo A Ruiz-Bedoya; Timothy D Read; Charles A Peloquin; Nathan K Archer; Lloyd S Miller; Kimberly M Davis; Jogarao V S Gobburu; Sanjay K Jain
Journal:  Sci Transl Med       Date:  2021-12-01       Impact factor: 17.956

3.  In vitro activities of rifapentine and rifampin, alone and in combination with six other antibiotics, against methicillin-susceptible and methicillin-resistant staphylococci of different species.

Authors:  P E Varaldo; E Debbia; G C Schito
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.